PDF(Pubmed)
Abstract：
UNASSIGNED: Retroperitoneal lymphatic malformations (LMs) are rare. Currently, the treatment of retroperitoneal LMs remains challenging. This study aimed to examine the safety and efficacy of laparoscopic-assisted sclerotherapy for retroperitoneal LMs in pediatric patients.
UNASSIGNED: We retrospectively reviewed patients treated with laparoscopic-assisted sclerotherapy for retroperitoneal LMs in a single tertiary medical center between July 2020 and February 2023. Doxycycline was prepared into a solution with a concentration of 10 mg/ml for use in sclerotherapy. Demographic data, clinical features, details of management, and outcomes were collected and analyzed.
UNASSIGNED: A total of six patients, comprising three males and three females, were identified. The LMs were categorized into four macrocystic and two mixed-cystic types. The mean age and weight were 52.2 months (range, 11-108 months) and 20 kg (range, 12.5-27.5 kg), respectively. Three patients presented with abdominal pain or distension, while the other three patients were asymptomatic. All six patients underwent a total of eight sclerotherapy sessions. Two patients experienced intra-cystic hemorrhage and required a second sclerotherapy session. Only one patient presented with vomiting after sclerotherapy, which resolved spontaneously. Five patients met the complete response criteria, and one patient met the effective criteria. The mean reduction in lesion size was 92.3% (range, 69.9%-99.6%). No further complications or recurrence were recorded during follow-up.
UNASSIGNED: Laparoscopic-assisted sclerotherapy is a safe and effective approach for treating retroperitoneal LMs. This technique is applicable for both macrocystic and mixed-cystic retroperitoneal LMs.
UNASSIGNED: We retrospectively reviewed patients treated with laparoscopic-assisted sclerotherapy for retroperitoneal LMs in a single tertiary medical center between July 2020 and February 2023. Doxycycline was prepared into a solution with a concentration of 10 mg/ml for use in sclerotherapy. Demographic data, clinical features, details of management, and outcomes were collected and analyzed.
UNASSIGNED: A total of six patients, comprising three males and three females, were identified. The LMs were categorized into four macrocystic and two mixed-cystic types. The mean age and weight were 52.2 months (range, 11-108 months) and 20 kg (range, 12.5-27.5 kg), respectively. Three patients presented with abdominal pain or distension, while the other three patients were asymptomatic. All six patients underwent a total of eight sclerotherapy sessions. Two patients experienced intra-cystic hemorrhage and required a second sclerotherapy session. Only one patient presented with vomiting after sclerotherapy, which resolved spontaneously. Five patients met the complete response criteria, and one patient met the effective criteria. The mean reduction in lesion size was 92.3% (range, 69.9%-99.6%). No further complications or recurrence were recorded during follow-up.
UNASSIGNED: Laparoscopic-assisted sclerotherapy is a safe and effective approach for treating retroperitoneal LMs. This technique is applicable for both macrocystic and mixed-cystic retroperitoneal LMs.
摘要：
■腹膜后淋巴畸形（LM）很少见。目前,腹膜后LMs的治疗仍然具有挑战性.这项研究旨在检查腹腔镜辅助硬化治疗小儿腹膜后LM的安全性和有效性。
■我们回顾性回顾了2020年7月至2023年2月在一个三级医疗中心接受腹腔镜辅助硬化治疗腹膜后LM的患者。将强力霉素制备成浓度为10mg/ml的溶液用于硬化治疗。人口统计数据,临床特征,管理细节，并对结局进行收集和分析.
■共有6名患者,包括三名男性和三名女性，已确定。LM分为四种大囊型和两种混合囊型。平均年龄和体重为52.2个月(范围，11-108个月）和20公斤（范围，12.5-27.5千克),分别。三名患者出现腹痛或腹胀，而其他三名患者无症状。所有6名患者总共接受了8次硬化治疗。两名患者出现囊内出血，需要第二次硬化治疗。只有一名患者在硬化治疗后出现呕吐，自发解决。五名患者符合完整的反应标准，一名患者符合有效标准。病变大小的平均减少为92.3%(范围，69.9%-99.6%）。随访期间无进一步并发症或复发。
■腹腔镜辅助硬化疗法是治疗腹膜后LMs的一种安全有效的方法。该技术适用于大囊性和混合囊性腹膜后LMs。
■我们回顾性回顾了2020年7月至2023年2月在一个三级医疗中心接受腹腔镜辅助硬化治疗腹膜后LM的患者。将强力霉素制备成浓度为10mg/ml的溶液用于硬化治疗。人口统计数据,临床特征,管理细节，并对结局进行收集和分析.
■共有6名患者,包括三名男性和三名女性，已确定。LM分为四种大囊型和两种混合囊型。平均年龄和体重为52.2个月(范围，11-108个月）和20公斤（范围，12.5-27.5千克),分别。三名患者出现腹痛或腹胀，而其他三名患者无症状。所有6名患者总共接受了8次硬化治疗。两名患者出现囊内出血，需要第二次硬化治疗。只有一名患者在硬化治疗后出现呕吐，自发解决。五名患者符合完整的反应标准，一名患者符合有效标准。病变大小的平均减少为92.3%(范围，69.9%-99.6%）。随访期间无进一步并发症或复发。
■腹腔镜辅助硬化疗法是治疗腹膜后LMs的一种安全有效的方法。该技术适用于大囊性和混合囊性腹膜后LMs。
